Literature DB >> 23610104

Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.

Andrea K Ng1, Judy E Garber, Lisa R Diller, Robyn L Birdwell, Yang Feng, Donna S Neuberg, Barbara Silver, David C Fisher, Karen J Marcus, Peter M Mauch.   

Abstract

PURPOSE: Current guidelines recommend breast magnetic resonance imaging (MRI) as an adjunct to mammography for breast cancer screening in female cancer survivors treated with chest irradiation at a young age, beginning 8 to 10 years after treatment. Prospective data evaluating its efficacy in female cancer survivors are lacking. This study sought to compare the sensitivity and specificity of breast MRI with those of mammography in women who received chest irradiation for Hodgkin lymphoma (HL). PATIENTS AND METHODS: We enrolled 148 women treated with chest irradiation for HL at age ≤ 35 years who were > 8 years beyond treatment. Yearly breast MRI and mammogram were performed over a 3-year period. Sensitivity and specificity of the two screening modalities were compared.
RESULTS: With the screening, 63 biopsies were performed in 45 women; 18 (29%) showed a malignancy. All but one of the screen-detected malignancies were preinvasive or subcentimeter node-negative breast cancers. After excluding first-screen MRI and mammogram, mammogram sensitivity was 68% as compared with 67% for MRI (P = 1.0). Sensitivity increased to 94% using both screening modalities. The specificities of mammogram alone, MRI alone, and both were 93%, 94%, and 90%, respectively.
CONCLUSION: In contrast to women with genetic or familial risk, in HL survivors breast MRI was not more sensitive than mammogram for breast cancer detection. However, the two screening modalities complement each other in the detection of early cases of disease. Early diagnosis is particularly important in these patients, given the breast cancer treatment challenges in patients who have received prior cancer therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23610104     DOI: 10.1200/JCO.2012.46.5732

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.

Authors:  Anna M Chiarelli; Kristina M Blackmore; Derek Muradali; Susan J Done; Vicky Majpruz; Ashini Weerasinghe; Lucia Mirea; Andrea Eisen; Linda Rabeneck; Ellen Warner
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

2.  Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM.

Authors:  Giovanna Mariscotti; Paolo Belli; Daniela Bernardi; Beniamino Brancato; Massimo Calabrese; Luca A Carbonaro; Beatrice Cavallo-Marincola; Francesca Caumo; Paola Clauser; Laura Martinchich; Stefania Montemezzi; Pietro Panizza; Federica Pediconi; Alberto Tagliafico; Rubina M Trimboli; Chiara Zuiani; Francesco Sardanelli
Journal:  Radiol Med       Date:  2016-07-12       Impact factor: 3.469

3.  Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD.

Authors:  B Frey Tirri; P Häusermann; H Bertz; H Greinix; A Lawitschka; C-P Schwarze; D Wolff; J P Halter; D Dörfler; R Moffat
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

4.  Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.

Authors:  Renée L Mulder; Melissa M Hudson; Smita Bhatia; Wendy Landier; Gill Levitt; Louis S Constine; W Hamish Wallace; Flora E van Leeuwen; Cécile M Ronckers; Tara O Henderson; Chaya S Moskowitz; Danielle N Friedman; Andrea K Ng; Helen C Jenkinson; Charlotte Demoor-Goldschmidt; Roderick Skinner; Leontien C M Kremer; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2020-09-29       Impact factor: 44.544

Review 5.  Solid tumor second primary neoplasms: who is at risk, what can we do?

Authors:  Kevin C Oeffinger; Shrujal S Baxi; Danielle Novetsky Friedman; Chaya S Moskowitz
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

Review 6.  Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review.

Authors:  Lucie M Turcotte; Joseph P Neglia; Raoul C Reulen; Cecile M Ronckers; Flora E van Leeuwen; Lindsay M Morton; David C Hodgson; Yutaka Yasui; Kevin C Oeffinger; Tara O Henderson
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

7.  Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Matthew J Ehrhardt; Carrie R Howell; Karen Hale; Malek J Baassiri; Carol Rodriguez; Carmen L Wilson; Surekha S Joshi; Thomas C Lemond; Sheila Shope; Rebecca M Howell; Zhaoming Wang; Deokumar Srivastava; Daniel A Mulrooney; Jinghui Zhang; Leslie L Robison; Kirsten K Ness; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2019-05-10       Impact factor: 44.544

Review 8.  Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature.

Authors:  Nadia Besson; Victor Pernin; Sofia Zefkili; Youlia M Kirova
Journal:  Br J Radiol       Date:  2016-01-08       Impact factor: 3.039

9.  Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results.

Authors:  Janice S Sung; Sarah Stamler; Jennifer Brooks; Jennifer Kaplan; Tammy Huang; D David Dershaw; Carol H Lee; Elizabeth A Morris; Christopher E Comstock
Journal:  Radiology       Date:  2016-04-20       Impact factor: 11.105

Review 10.  Risk Reduction Strategies in Breast Cancer Prevention.

Authors:  Mauricio Costa; Paula Saldanha
Journal:  Eur J Breast Health       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.